Rapid generation of full clinical-grade human antiadenovirus cytotoxic t cells for adoptive immunotherapy

Journal of Immunotherapy

Volumn 33, Issue 4, 2010, Pages 414-424

  Aïssi Rothe, Lamia ^a,c   Decot, Véronique ^a,c   Venard, Véronique ^a   Jeulin, Helene ^a   Salmon, Alexandra ^b   Clement, Laurence ^a   Kennel, Anne ^a   Mathieu, Christine ^a   Dalle, Jean Hugues ^d   Rauser, Georg ^e   Cambouris, Christophe ^e   De Carvalho, Marcelo ^a   Stoltz, Jean François ^a,c   Bordigoni, Pierre ^b   Bensoussan, Danièle ^a,c  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b HÔPITAL D ENFANTS   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e MILTENYI BIOTEC GMBH   (Germany)

Author keywords

Adenovirusspecific t cells; Adoptive immunotherapy; Hematopoietic stem cell transplantation; Synthetic peptide pool

Indexed keywords

GAMMA INTERFERON; PROTEIN HEXON; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS PROTEIN;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; QUALITY CONTROL; T LYMPHOCYTE;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANTIGENS, CD4; CAPSID PROTEINS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77954894222     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181cc263b     Document Type: Article

References (37)

1. Handgretinger R, Lang P, Schumm M, et al. Immunological aspects of haploidentical stem cell transplantation in children. Ann N Y Acad Sci. 2001;938:340-357.
2. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994;331:679-680.
3. Zaia JA, Sissons JG, Riddell S, et al. Status of cytomegalovirus prevention and treatment in 2000. Hematol Am Soc Hematol Educ Prog. 2000:339-355.
4. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619-1627.
5. Cavazzana-Calvo M, Bensoussan D, Jabado N, et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. Br J Haematol. 1998;103:543-551.
6. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502-1505.
7. Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis. 1994;169:775-781.
8. Kampmann B, Cubitt D, Walls T, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol. 2005;130:595-603.
9. van Tol MJ, Kroes AC, Schinkel J, et al. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant. 2005;36:39-50.
10. Lewin SR, Heller G, Zhang L, et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood. 2002;100:2235-2242.
11. Feuchtinger T, Lucke J, Hamprecht K, et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2005;128:503-509.
12. Heemskerk B, Lankester AC, van Vreeswijk T, et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis. 2005;191:520-530.
13. Myers GD, Bollard CM, Wu MF, et al. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39:677-686.
14. Bordigoni P, Carret AS, Venard V, et al. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:1290-1297. (Pubitemid 32405900)
15. Feuchtinger T, Lang P, Hamprecht K, et al. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol. 2004;32:282-289.
16. Hromas R, Cornetta K, Srour E, et al. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood. 1994;84:1689-1690.
17. Childs R, Sanchez C, Engler H, et al. High incidence of adenoand polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine. Bone Marrow Transplant. 1998;22:889-893.
18. Chakrabarti S, Collingham KE, Fegan CD, et al. Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy? Bone Marrow Transplant. 2000;26:305-307.
19. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virusinduced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
20. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
21. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922.
22. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-1166.
23. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134:64-76.
24. Tang J, Olive M, Pulmanausahakul R, et al. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology. 2006;350:312-322.
25. Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant. 2007;13:74-81.
26. Leen AM, Heslop HE. Cytotoxic T lymphocytes as immunetherapy in haematological practice. Br J Haematol. 2008;143:169-179.
27. Maecker HT, Dunn HS, Suni MA, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001;255:27-40.
28. Kiecker F, Streitz M, Ay B, et al. Analysis of antigen-specific T-cell responses with synthetic peptides-what kind of peptide for which purpose? Hum Immunol. 2004;65:523-536.
29. Feuchtinger T, Richard C, Joachim S, et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother. 2008;31:199-206.
30. Tramsen L, Koehl U, Tonn T, et al. Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant. 2009;43:13-19.
31. Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol. 2004;5:927-933.
32. Fujita Y, Leen AM, Sun J, et al. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008;31:665-674.
33. Chatziandreou I, Gilmour KC, McNicol AM, et al. Capture and generation of adenovirus specific T cells for adoptive immunotherapy. Br J Haematol. 2007;136:117-126.
34. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol. 2006;6:417-423.
35. Lewalle P, Triffet A, Delforge A, et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant. 2003;31:39-44.
36. Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood. 2004;103:3565-3572.
37. Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958-1967.